The influence of regulatory T cells on dendritic cells in mice with hepatocellular carcinoma
DU Yong1, HUANG Zhiming2, LIN Xiuqing2, CHEN Xin2.
1.Department of Pediatrics, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325015; 2.Department of Gastroenterology and Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325015
DU Yong,HUANG Zhiming,LIN Xiuqing, et al. The influence of regulatory T cells on dendritic cells in mice with hepatocellular carcinoma[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2017, 47(10): 718-722.
Abstract：Objective: To investigate how CD4+CD25+ regulatory T cells (Tregs)impacted on dendritic cells which were separated from BALB/c mice with hepatocellular carcinoma. Methods: BALB/c mice with hepatocellular carcinoma were established in laboratory. Twenty-five days after the models, the tumor-bearing mice were sacrificed and fresh spleen tissues were separated. Tregs, CD4+CD25-T cells and dendritic cells were separated from the mice’s spleen and purified by immuno-magnetic beads according to the manufacturers’ instructions. Tregs were co-cultured with CD4+CD25-T cells and the proliferation experiment was measured with CCK8. Tregs were directly co-cultured with dendritic cells and then the expression of CD80/CD86 on dendritic cells was detected by flow cytometry. The levels of TNF-α and IL-12 in supernatants were detected by ELISA. Results: We successfully established the tumor model of hepatocellular carcinoma and obtained high purity of Tregs, CD4+CD25-T cells and dendritic cells. Tregs could suppress the proliferation of CD4+CD25-T cells in vitro. Tregs could down-regulate the expression of CD80/CD86 on dendritic cells and inhibit the expression of TNF-α and IL-12. Conclusion: Tregs play an important role in the establishment and persistence of tumor immune suppression. Tregs can inhibit the function of dendritic cells in tumor-bearing mice. So Tregs may be a promising therapeutic target for cancer.
[1] ANGUILLE S, SMITS E L, LION E, et al. Clinical use of dendritic cells for cancer therapy[J]. Lancet Oncol, 2014, 15(7): e257-e267.
[2] PEDROZA-GONZALEZ A, VERHOEF C, IJZERMANS J N, et al. Activated tumor infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer[J]. Hepatology, 2013, 57(1): 183-194.
[3] 张海英, 李艳茹, 王健君, 等. 小鼠原位移植性肝癌模型的建立及生物学特性[J]. 吉林大学学报(医学版), 2009, 35: 5-8.
[4] 蒋卫平, 丁茂文, 朱亚非, 等. 实时荧光定量RT-PCR检测人外周血单个核细胞中FOXP3 mRNA的表达[J]. 温州医学院学报, 2009, 39(6): 595-598.
[5] 陈坛辀, 金瑞放, 黄智铭, 等. CD4+CD25+Foxp3调节性T细胞在人幽门螺杆菌感染后胃黏膜中的表达[J]. 温州医学院学报, 2011, 41(2): 149-152.
[6] YANG P, LI Q J, FENG Y, et al. TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma[J].Cancer Cell, 2012, 22(3): 291-303.
[7] CHEN M L, YAN B S, LU W C, et al. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity [J]. Int J Cancer, 2014, 134(2): 319-331.
[8] BLANK C U, ENK A. Therapeutic use of anti-CTLA-4 antibodies[J]. Int Immunol, 2015, 27(1): 3-10.
[9] YI Y, HE H W, WANG J X, et al. The functional impairment of HCC-infiltrating γδ T cells, partially mediated by regulatory T cells in a TGFβ- and IL-10-dependent manner[J]. J Hepatol, 2013, 58(5): 977-983.
[10] ROTHSTEIN D M, CAMIRAND G. New insights into the mechanisms of Treg function[J]. Curr Opin Organ Transplant, 2015, 20(4): 376-384
